| Q89893294 | Alternative Lengthening of Telomeres: Building Bridges To Connect Chromosome Ends |
| Q89664688 | Androgen receptor-binding sites are highly mutated in prostate cancer |
| Q90664270 | CDK1 dependent phosphorylation of hTERT contributes to cancer progression |
| Q112724548 | Cancer-specific loss of TERT activation sensitizes glioblastoma to DNA damage |
| Q94687033 | Coding and noncoding somatic mutations in candidate genes in basal cell carcinoma |
| Q57797239 | Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behaviour of bladder cancer |
| Q57787252 | DNA hypermethylation within TERT promoter upregulates TERT expression in cancer |
| Q92887487 | Deep sequencing of a recurrent oligodendroglioma and the derived xenografts reveals new insights into the evolution of human oligodendroglioma and candidate driver genes |
| Q91385901 | Disruption of the β1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner |
| Q49545769 | Dynamics of human telomerase recruitment depend on template- telomere base pairing |
| Q50054621 | Dysfunctional telomeres and hematological disorders. |
| Q55495686 | ETS transcription factors induce a unique UV damage signature that drives recurrent mutagenesis in melanoma. |
| Q47224965 | ETS1, nucleolar and non-nucleolar TERT expression in nevus to melanoma progression |
| Q90719450 | Evolving Insights into the Molecular Neuropathology of Diffuse Gliomas in Adults |
| Q88476212 | Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma |
| Q90128325 | Genome rearrangements associated with aberrant telomere maintenance |
| Q61805743 | Identification of genes involved in the regulation of TERT in hepatocellular carcinoma |
| Q97542867 | Identification of shared genomic aberrations between angiomatous and microcystic meningiomas |
| Q89777623 | Maintenance of telomere length in AML |
| Q52727349 | Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer. |
| Q91723523 | Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players |
| Q47227422 | Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells |
| Q52343716 | Molecular genomic landscapes of hepatobiliary cancer. |
| Q52725991 | Montagna Symposium 2017-Precision Dermatology: Next Generation Prevention, Diagnosis, and Treatment. |
| Q58595545 | New generation cancer therapy: right direction for sure with some uncertainty |
| Q57457238 | Novel immune signatures associated with dysplastic nevi and primary cutaneous melanoma in human skin |
| Q92564137 | PITX1 protein interacts with ZCCHC10 to regulate hTERT mRNA transcription |
| Q90318108 | Pathogenic TERT promoter variants in telomere diseases |
| Q52608306 | Reconstructing the molecular life history of gliomas. |
| Q91884598 | Recurrent Noncoding Mutations in Skin Cancers: UV Damage Susceptibility or Repair Inhibition as Primary Driver? |
| Q91522991 | Regulation of human telomerase in homeostasis and disease |
| Q64243404 | Revisiting Telomere Shortening in Cancer |
| Q59332881 | SMuRF: a novel tool to identify regulatory elements enriched for somatic point mutations |
| Q55465529 | Short- and long-term evolution in our arms race with cancer: Why the war on cancer is winnable. |
| Q98771221 | TERT Promoter Mutation C228T Increases Risk for Tumor Recurrence and Death in Head and Neck Cancer Patients |
| Q49957857 | TERT promoter mutation in adult granulosa cell tumor of the ovary. |
| Q64114386 | TERT promoter mutations in melanoma survival |
| Q90749197 | TERT, a promoter of CNS malignancies |
| Q98177214 | Targeting telomerase for cancer therapy |
| Q64055352 | Targeting the ERK Signaling Pathway in Melanoma |
| Q90211132 | Telomerase Biology Associations offer Keys to Cancer and Aging Therapeutics |
| Q55443450 | Telomere Maintenance Mechanisms in Cancer. |
| Q96224238 | Telomere dysfunction activates p53 and represses HNF4α expression leading to impaired human hepatocyte development and function |
| Q90351399 | Telomere length and survival in primary cutaneous melanoma patients |
| Q91379882 | Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma risk |
| Q52714796 | Telomere sequence content can be used to determine ALT activity in tumours. |
| Q89976278 | Telomeres and Telomere Length: A General Overview |
| Q90682184 | The Mutational Landscape of Pancreatic and Liver Cancers, as Represented by Circulating Tumor DNA |
| Q90596932 | The Solo Play of TERT Promoter Mutations |
| Q89470187 | The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival |
| Q59332936 | The ins and outs of telomere crisis in cancer |
| Q90145180 | The prognostic significance of TERT promoter mutations in meningioma: a systematic review and meta-analysis |
| Q93117015 | The role of telomeres and telomerase in cirrhosis and liver cancer |
| Q90744618 | Therapeutic Targets in Telomerase and Telomere Biology of Cancers |
| Q90917856 | Transcriptome analysis of papillary thyroid cancer harboring telomerase reverse transcriptase promoter mutation |
| Q52662392 | When the Ends Are Really the Beginnings: Targeting Telomerase for Treatment of GBM. |